Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.
Official title: Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
Key Details
Gender
All
Age Range
2 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2024-07-29
Completion Date
2026-12-31
Last Updated
2024-08-27
Healthy Volunteers
No
Conditions
Interventions
Tofacitinib
In the real-world settings, patients with AA treated with tofacitinib.
Baricitinib
In the real-world settings, patients with AA treated with Baricitinib.
Ruxolitinib
In the real-world settings, patients with AA treated with Ruxolitinib.
Upadacitinib
In the real-world settings, patients with AA treated with Upadacitinib.
Abrocitinib
In the real-world settings, patients with AA treated with Abrocitinib.
Ritlecitinib
In the real-world settings, patients with AA treated with Ritlecitinib.
Locations (1)
Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China